On January 17, 2019, the Federal Court of Appeal heard the Attorney General of Canada’s appeal from a judicial review that quashed a Board decision that it has jurisdiction over Galderma’s DIFFERIN (0.1% adapalene). Our report on the Federal Court decision, 2017 FC 1023, is found here. Innovative Medicines Canada intervened in the appeal. The Federal Court of Appeal reserved judgment.
Related Publications & Articles
-
Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines outlines proposed new framework for patented medicine price review
This article provides an overview of the price review framework proposed by the PMPRB and key topics on which stakeholder feedback is sought.Read More -
Manitoba last province to introduce Biosimilars Initiative, while Ontario adds four drugs to its Biosimilar Policy
Manitoba has implemented a Biosimilars Initiative effective August 1, 2024.Read More -
Boehringer Ingelheim succeeds in nintedanib PMNOC action against JAMP
In a public decision dated August 8, 2024, Justice Furlanetto of the Federal Court found Boehringer Ingelheim’s Canadian Patent No. 2,591,083 (the 083 patent) valid and infringed by JAMP in an action ...Read More